Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/ritonavir and myocardial injury in SARS-CoV-2 infection
ChiCTR2200063778Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nirmatrelvir + ritonavir in coronavirus disease 2019 (COVID-19), Myocardial injury and cardiac morbidity (2 cohorts), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Incidence of myocardial injury. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
nirmatrelvir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)Myocardial injurycardiac morbidity
Beyond the preview
Go deeper on ChiCTR2200063778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063778.